Januvia, Janumet, Victoza and Byetta: New dangers associated with Incretin Mimetic drugs for diabetics
The F.D.A. recently announced it
was reviewing a study involving Incretin Mimetic drugs. These drugs work to
treat type 2 diabetes but have been linked to acute pancreatitis. Further, the
study that is the subject of the FDA review purports to show that there is also
an increased risk of pancreatic
and thyroid cancers. The drug may cause an increase in tumors in the
thyroid and pancreas which could become malignant (cancerous).
With 25 million diabetics in the
United States, Incretin Memetic drugs comprise a large segment of the diabetes
drug market. These drugs include Januvia,
Janumet, Byetta and Victoza. Januvia, for instance, brought in revenue over
$4 Billion. Janumet, a combination of Januvia and another popular drug,
(Metformin) had sales of $1.65 Billion.
With the changing safety profile of
these drugs, new concerns about their efficacy and benefits have been raised. A
number of lawsuits have been initiated against the products manufacturers.
Rudolph F.X. Migliore, P.C. is
working with nationally recognized associated firms to litigate claims against
these diabetes drugs manufacturers for allegedly causing pancreatic or thyroid
cancer. At the New York law office of Rudolph F. X. Migliore, more than 35
years of experience gives us the knowledge to tackle complicated product
liability cases for our clients and help them obtain compensation for their
injuries. To schedule a free case evaluation, visit Migliorelaw.com or call us toll free
at 1-888-980-RFXM (7396).
No comments:
Post a Comment